Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Summary of Post-Operative Therapy: Part 2 of Lecture from Cancer Lifeline
Author
Howard (Jack) West, MD

This slide presentation is the second part of a lecture I gave at the Seattle-based non-profit Cancer Lifeline a few months ago. This covers the evidence supporting post-operative (adjuvant) chemotherapy for patients with early stage NSCLC, the need to recognize that this does not apply to all patients who have undergone surgery, and the emerging clinical research and ongoing trials that may lead to improvements in our cure rate for early stage NSCLC patients in the future.

Here is the presentation in video format, the audio version, transcript, and a pdf file of the figures. I hope it's helpful.

[powerpress]

Cancer Lifeline Part 2 Adjuvant Therapy Early Stage NSCLC Audio Podcast

cancer-lifeline-part-2-adjuvant-therapy-early-stage-nsclc-transcript

cancer-lifeline-part-2-adjuvant-therapy-early-stage-nsclc-figures

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.